SCHEMBL5013532

SCHEMBL5013532

COc1ccc(F)cc1C(=O)Nc1cc(C(=O)NCc2ccccc2)n[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.52
TP53 P04637 2/20 0.52
GLA P06280 1/20 0.52
ALDH1A1 P00352 4/20 0.48
LMNA P02545 3/20 0.48
MAPT P10636 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 2/20 0.48
KDM4E B2RXH2 1/20 0.48
PPARA Q07869 4/20 0.46
PPARG P37231 3/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
POLB P06746 2/20 0.46
KCNH2 Q12809 2/20 0.45
GRIN2B Q13224 1/20 0.45
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5012123 0.89 HPGD (0.50) HPGDTP53GLAALDH1A1LMNA
SCHEMBL5012227 0.87 HTT (0.47) HPGDALDH1A1LMNAMAPTNPSR1
SCHEMBL5013518 0.86 HSP90AA1 (0.46) HPGDPPARGKMT2ATHRB
SCHEMBL5013581 0.86 PPARG (0.55) PPARGKMT2A
SCHEMBL5013503 0.84 PPARG (0.50) ALDH1A1SMN1; SMN2PPARGKMT2A
SCHEMBL5008318 0.83 PPARG (0.47) HPGDTP53ALDH1A1MAPTNPSR1
SCHEMBL5010346 0.82 PPARG (0.48) HPGDTP53ALDH1A1LMNAMAPT
SCHEMBL5009769 0.81 PPARG (0.47) TP53MAPTPPARGKMT2APOLB
SCHEMBL5008281 0.79 SMN1; SMN2 (0.55) HPGDALDH1A1LMNAMAPTNPSR1
SCHEMBL5009736 0.79 APP (0.48) TP53MAPTSMN1; SMN2KDM4EPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL HPGD 3765/4885TP53 3885/4885GLA 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.